
Carter Gould
Stock Analyst at Cantor Fitzgerald
(4.44)
# 1,213
Out of 5,189 analysts
654
Total ratings
54.1%
Success rate
7.3%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Reiterated: Hold | $155 | $133.72 | +15.91% | 49 | Nov 12, 2026 | |
| AMGN Amgen | Reiterated: Hold | $440 → $465 | $435.64 | +6.74% | 53 | Nov 3, 2026 | |
| PFE Pfizer | Reiterated: Hold | $28 | $27.40 | +2.19% | 63 | Nov 3, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $595 → $619 | $515.02 | +20.19% | 13 | Nov 2, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $290 → $325 | $286.20 | +13.56% | 52 | Nov 1, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,440 → $1,600 | $1,347.11 | +18.77% | 103 | Nov 1, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $795 → $980 | $920.69 | +6.44% | 54 | Nov 1, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | $53 | $58.80 | -9.86% | 38 | Oct 29, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $155 → $175 | $166.43 | +5.15% | 53 | Oct 29, 2026 | |
| PCVX Vaxcyte | Reiterated: Buy | $120 | $55.39 | +116.65% | 3 | Oct 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $50.78 | - | 18 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $249.59 | n/a | 45 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.72 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $47.00 | n/a | 24 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $19.19 | n/a | 14 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $0.8707 | n/a | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $2.34 | n/a | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $150.57 | n/a | 29 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $160 | $155.89 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $141.33 | n/a | 1 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | โฌ84.81 | โฌ146.45 | n/a | 1 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $82 → $86 | $114.63 | n/a | 4 | Jul 31, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $94 | $554.73 | n/a | 1 | May 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $4 | $1.95 | n/a | 2 | Feb 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $2.8 | $6.14 | n/a | 2 | Jan 11, 2019 |
Merck & Co.
Nov 12, 2026
Reiterated: Hold
Price Target: $155
Current: $133.72
Upside: +15.91%
Amgen
Nov 3, 2026
Reiterated: Hold
Price Target: $440 → $465
Current: $435.64
Upside: +6.74%
Pfizer
Nov 3, 2026
Reiterated: Hold
Price Target: $28
Current: $27.40
Upside: +2.19%
Vertex Pharmaceuticals
Nov 2, 2026
Reiterated: Buy
Price Target: $595 → $619
Current: $515.02
Upside: +20.19%
AbbVie
Nov 1, 2026
Reiterated: Buy
Price Target: $290 → $325
Current: $286.20
Upside: +13.56%
Eli Lilly and Company
Nov 1, 2026
Reiterated: Buy
Price Target: $1,440 → $1,600
Current: $1,347.11
Upside: +18.77%
Regeneron Pharmaceuticals
Nov 1, 2026
Reiterated: Buy
Price Target: $795 → $980
Current: $920.69
Upside: +6.44%
Bristol-Myers Squibb Company
Oct 29, 2026
Reiterated: Hold
Price Target: $53
Current: $58.80
Upside: -9.86%
Gilead Sciences
Oct 29, 2026
Reiterated: Buy
Price Target: $155 → $175
Current: $166.43
Upside: +5.15%
Vaxcyte
Oct 12, 2026
Reiterated: Buy
Price Target: $120
Current: $55.39
Upside: +116.65%
Feb 25, 2026
Reiterated: Buy
Price Target: n/a
Current: $50.78
Upside: -
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $249.59
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $10.72
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $47.00
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $19.19
Upside: n/a
Nov 8, 2024
Rated: Buy
Price Target: $9
Current: $0.8707
Upside: n/a
Nov 7, 2024
Reiterated: Buy
Price Target: $12
Current: $2.34
Upside: n/a
Oct 31, 2024
Reiterated: Buy
Price Target: $160
Current: $150.57
Upside: n/a
Jan 11, 2023
Rated: Hold
Price Target: $160
Current: $155.89
Upside: n/a
Dec 7, 2022
Initiated Coverage: Buy
Price Target: $37
Current: $141.33
Upside: n/a
Feb 27, 2020
Initiated Coverage: Buy
Price Target: โฌ84.81
Current: โฌ146.45
Upside: n/a
Jul 31, 2019
Reiterated: Hold
Price Target: $82 → $86
Current: $114.63
Upside: n/a
May 17, 2019
Upgraded: Hold
Price Target: $94
Current: $554.73
Upside: n/a
Feb 1, 2019
Downgraded: Hold
Price Target: $16 → $4
Current: $1.95
Upside: n/a
Jan 11, 2019
Reiterated: Hold
Price Target: $6 → $2.8
Current: $6.14
Upside: n/a